https://glp1-news.nicheflash.com/ 2026-06-19T11:32:11+00:00 daily 1.0 https://glp1-news.nicheflash.com/blogs 2026-06-19T11:32:11+00:00 daily 0.9 https://glp1-news.nicheflash.com/about 2026-06-19T11:32:11+00:00 monthly 0.5 https://glp1-news.nicheflash.com/disclaimer 2026-06-19T11:32:11+00:00 yearly 0.3 https://glp1-news.nicheflash.com/privacy-policy 2026-06-19T11:32:11+00:00 yearly 0.3 https://glp1-news.nicheflash.com/blogs/bone-health-glp-1s-2026-study-data-conflict 2026-08-29T00:43:43+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/bmj-study-glp-1-drugs-hair-loss-alopecia-risk 2026-08-18T18:44:09+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/shifting-glp-1-delivery-oral-approvals-and-monthly-dosing 2026-08-08T12:54:31+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/lillys-retatrutide-hits-30-weight-loss-threshold-in-phase-3 2026-08-02T12:56:25+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/kidney-benefits-of-semaglutide-solidify-with-2026-data 2026-08-02T12:54:58+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/medicare-glp-1-bridge-launches-july-2026-coverage-and-eligibility 2026-08-02T12:59:17+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/untitled-4 2026-08-02T12:47:09+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/untitled-3 2026-08-02T12:46:20+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/glp-1-heart-benefits-type-1-diabetes-2026 2026-08-02T12:48:44+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/untitled-2 2026-08-02T12:45:34+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/untitled 2026-08-02T12:44:47+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/beyond-efficacy-glp1-adherence-challenges 2026-08-02T12:47:56+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/fda-flags-novo-nordisk-glp1-safety-reporting-gaps 2026-08-02T12:52:41+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/redefine-4-cagrisema-misses-non-inferiority-against-tirzepatide 2026-08-02T12:58:33+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/new-large-scale-study-links-glp-1-drugs-lower-addiction-risk 2026-08-02T12:57:07+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/mazdutide-surpasses-semaglutide-in-head-to-head-phase-3-trial 2026-08-02T12:57:50+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/new-data-reveals-lean-mass-loss-linked-to-glp-1-meds 2026-08-02T12:54:13+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/boehringers-survodutide-16-6-weight-loss-phase-3 2026-08-02T12:51:54+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/fda-approves-orforglipron-daily-oral-glp-1 2026-08-02T12:49:31+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/retatrutides-29-weight-loss-triple-agents-rise 2026-08-02T12:51:07+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/glp-1-market-shifts-patent-expiries-trial-setbacks 2026-08-02T12:53:28+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/tirzepatide-cv-findings-medicare-glp-1-bridge 2026-08-02T12:50:18+00:00 weekly 0.8 https://glp1-news.nicheflash.com/blogs/oral-wegovy-higher-dose-semaglutide-compounding-limits 2026-08-02T12:55:42+00:00 weekly 0.8